<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471677</url>
  </required_header>
  <id_info>
    <org_study_id>elonva_hyper-responders</org_study_id>
    <nct_id>NCT02471677</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa Versus Follitropin Beta in High Responders</brief_title>
  <official_title>Corifollitropin Alfa (Elonva) Versus Follitropin Beta in High Responders: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eugonia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eugonia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled trial (RCT) is to compare a single injection of
      corifollitropin-alfa versus daily injections of follitropin beta regarding the number of
      oocytes retrieved, hormonal profile and follicle development in patients with high response
      undergoing ovarian stimulation for in vitro fertilization treatment using a
      gonadotropin-releasing hormone (GnRH) antagonist protocol combined with GnRH agonist trigger
      and cryopreservation of all embryos.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corifollitropin alfa, a novel fusion protein lacking luteinizing hormone (LH) activity, has a
      longer elimination half-life and extended time to peak levels than recombinant follicle
      stimulating hormone (rFSH). A single injection of corifollitropin alfa may replace seven
      daily injections follitropin beta during the first week of ovarian stimulation, reducing
      patient discomfort.

      The purpose of this RCT is to compare a single injection of corifollitropin-alfa versus daily
      injections of follitropin beta regarding the number of oocytes retrieved, as well as hormonal
      profile and follicle development in patients with high response undergoing ovarian
      stimulation for IVF using a GnRH antagonist protocol. In addition, incidence of unexpected
      ovarian hyperstimulation syndrome (OHSS) will be evaluated, although it is anticipated that
      GnRH agonist triggering will eliminate occurrence of the syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>Day of oocyte retrieval (Day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe OHSS</measure>
    <time_frame>up to 5 days post oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle development</measure>
    <time_frame>Day of triggering final oocyte maturation = last day of ovarian stimulation (Day -2 prior to oocyte retrieval)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>Day 1 after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blastocyst formation rates</measure>
    <time_frame>Day 5/6 after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blastocysts cryopreserved</measure>
    <time_frame>Day 5/6 after oocyte retrieval</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Puregon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elonva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elonva</intervention_name>
    <description>corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle</description>
    <arm_group_label>Elonva</arm_group_label>
    <other_name>corifollitropin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Puregon</intervention_name>
    <description>follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved</description>
    <arm_group_label>Puregon</arm_group_label>
    <other_name>follitropin beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-40 years

          -  Polycystic ovaries (PCO) or polycystic ovary syndrome (PCOS)

          -  no endometriotic cyst

        Exclusion Criteria:

          -  Patients with poor response

          -  Patients using human chorionic gonadotropin (hCG) for triggering final oocyte
             maturation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trifon G Lainas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eugonia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trifon G Lainas, PhD</last_name>
    <phone>00302107236333</phone>
    <email>ivf@eugonia.com.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eugonia Unit of Assisted Reproduction</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trifon G Lainas, PhD</last_name>
      <phone>00302107236333</phone>
      <email>ivf@eugonia.com.gr</email>
    </contact>
    <investigator>
      <last_name>Trifon G Lainas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009 Dec;24(12):3063-72. doi: 10.1093/humrep/dep291. Epub 2009 Aug 14. Erratum in: Hum Reprod. 2014 May;29(5):1116-20.</citation>
    <PMID>19684043</PMID>
  </reference>
  <reference>
    <citation>Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM; Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2010 Nov;21(5):593-601. doi: 10.1016/j.rbmo.2010.06.032. Epub 2010 Jun 30.</citation>
    <PMID>20843746</PMID>
  </reference>
  <reference>
    <citation>Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update. 2009 May-Jun;15(3):309-21. doi: 10.1093/humupd/dmn065. Epub 2009 Jan 30. Review.</citation>
    <PMID>19182099</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian stimulation</keyword>
  <keyword>corifollitropin alfa</keyword>
  <keyword>GnRH antagonist protocol</keyword>
  <keyword>high responders</keyword>
  <keyword>follitropin beta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

